IPCS INCHEM Home


    ERYTHROSINE

    EXPLANATION

         Erythrosine was evaluated for an acceptable daily intake by the
    Joint FAO/WHO Expert Committee on Food Additives at its eighth,
    thirteenth, eighteenth, and twenty-eighth meetings (Annex 1,
    references 8, 19, 35, and 66). Toxicological monographs were published
    after the thirteenth, eighteenth, and twenty-eighth meetings (Annex 1,
    references 20, 36, and 62). At its eighteenth meeting the Committee
    allocated an ADI of 0-2.5 mg/kg b.w.; this was reduced at the
    twenty-eighth meeting to 0-1.25 mg/kg b.w. and made temporary
    following observtions that erythrosine produced effects on thyroid
    function in short-term studies in rats and that, in long-term studies,
    male rats receiving 4% erythrosine in the diet developed thyroid
    tumours (begnin follicular adenomas). The Committee requested further
    information on the histopathology (including diffuse hyperplasia) of
    all thyroid glands from the long-term studies in rats, the mechanism
    of the effects of erythrosine on the thyroid, and the existence of a
    threshold and reversibility of these effects. It was also considered
    desirable to have further information on the pharmacokinetics of
    erythrosine and its effect on thyroid function in human subjects.

         Since the previous evaluation, additional data have become
    available and are summarized and discussed in the following monograph.
    The previously-published monographs have been expanded and are
    reproduced in their entirety below.

    BIOLOGICAL DATA

    Biochemical aspects

         The metabolic behaviour and excretory pattern of erythrosine have
    been studied in adult rats. When the colour was given by stomach tube
    to male rats at levels as high as 150 mg/rat, recovery in the excreta
    after 5 days was 102%. After i.v. administration of 3 mg erythrosine
    per kg b.w., an average of 55% of the administered quantity was found
    in the bile and 1.3% was recovered in the urine. No glucuronic acid
    conjugation was found (Daniel, 1962).

         In studying the possibility that iodide may be liberated from
    erythrosine and disturb thyroid function in the rat, erythrosine was
    found to be metabolically stable; 100% of the amount ingested was
    excreted, with its iodine content intact, after administration of
    500 mg/kg erythrosine (Webb et al., 1962).

         The urinary and faecal excretion of 14C-labelled and of
    125I-labelled erythrosine were studied in rats of both sexes either
    without pre-treatment or following dosing with unlabelled erythrosine
    at dietary levels of 0.5 or 4.0% for 7 days. The distribution of the
    compound in tissues and body fluids was also studied.

         The radioactivity from both radiolabels was excreted
    predominantly in the faeces, mainly within 48 hours; less than 1% of
    the dose was excreted in urine. Blood and plasma radioactivity reached
    maximum levels by 1 hour, while levels in the liver and kidneys peaked
    after 4-12 hours. The activity in blood and tissues was very low,
    suggesting that erythrosine is not extensively absorbed from the
    gastrointestinal tract. Of the tissues examined (liver, kidney,
    thyroid, brain, and pituitary), the highest levels of radioactivity
    were found in the liver (maximally 0.145% of the dose of 14C; 0.188%
    of the dose of 125I). Thyroid residues of 14C were at trace or
    non-detectable levels, while levels of 125I were detectable but low
    (maximally approximately 0.01% of the dose), indicating that neither
    erythrosine nor its ring-containing metabolites accumulated in the
    thyroid. The magnitude of the 125I levels in the thyroid was so low
    that it was not possible to conclude whether the activity resulted
    from 125I-iodide in the dose or from 125I-iodide formed by a smell
    degree of metabolic deiodination of erythrosine. No 14C or 125I was
    detectable in the brain or pituitary. Smell amounts of metabolites,
    believed to be isomeric diiodo- and triiodofluoresceins, were detected
    in urine, faeces, plasma, and tissue extracts from the liver and kidney
    (Obrist et al., 1986).

         Protein-bound and total blood iodine levels were elevated in rats
    given erythrosine by stomach tubs twice weekly in a chronic study.
    However, in experiments with rats and gerbils, it was concluded that
    the elevated protein-bound iodine (PBI) was due to interference by
    erythrosine in PBI determinations (Bowie et al., 1966; U.S. FDA,
    1969).

         Large doses of erythrosine labelled with 131I given orally to
    rats inhibited uptake of 131I by the thyroid of treated animals.
    Daily doses of over 1 mg erythrosine were necessary for this effect to
    occur (Harignan et al., 1965).

         Studies were performed to investigate the effects of erythrosine
    on the metabolism of 125I-labelled thyroxine (T4) and
    triiodothyronine (T3) by rat liver homogenates. The rats were given
    i.p. daily doses of 2.5 - 250 mg erythrosine/kg b.w. in vivo prior
    to preparation of the liver homogenates. Erythrosine caused a
    dose-dependent inhibition of the deiodination of T4 and of the
    generation of T3. At dose levels of > 10 mg/kg b.w., the
    proportionate reduction in the deiodination of 125I-T4 exceeded
    the reduction in the generation of 125I-T3, indicating that
    pathways of T4 metabolism other than those leading to T3 formation
    were also inhibited. The authors concluded that erythrosine may
    inhibit the 5-monodeiodinat ion of T4 to reverse T3 (rT3) since
    erythrosine also inhibited the 5-monodeiodination of T3 to
    3,3'-diiodothyronine. Fluorescein did not exhibit similar effects. It
    was considered unlikely that erythrosine would produce similar effects
    in man in the doses normally ingested. This conclusion was supported
    by studies in human volunteers given oral doses of erythrosine of up
    to 25 mg daily for 7 days when no changes in serum T4, T3, or
    rT3 concentrations were detected (Ruiz & Ingbar, 1982;
    Garber et al., 1981).

         Six groups of 15 male Sprague-Dawley rats received 0, 0.25, 0.50,
    1.0, 2.0, or 4.0% erythrosine in the diet for a period of 7 months.
    After 6 months each group was divided into three sub-groups of 5 rats;
    during the next month one sub-group received 15 µg T3/kg b.w./day by
    s.c. injection, a second sub-group received the saline vehicle, and
    the third sub-group continued with no injections. Blood samples
    (orbital puncture) were obtained just before the start of the study
    and at monthly intervals thereafter and serum thyroid hormone levels
    were determined. At termination, pituitary glands and liver segments
    were excised and in vitro studies of T4 metabolism were performed
    on these tissues.

         Serum thyrotropin (TSH) levels were variable and, although mean
    serum TSH values were higher in the 4% erythrosine group than in the
    control or 0.5% groups over the first 6 months of the study, the
    differences were not statistically-significant.  Serum TSH

    concentrations in sub-groups which received injections of T3 during
    the final month were below detection limits (15 µU/ml). Serum T4
    concentrations were elevated relative to base-line and control values
    in animals receiving 4% erythrosine during the 6 months of the study,
    whereas the values for the control and 0.5% erythrosine groups did not
    differ significantly from base-line values or from each other. Serum
    T4 concentrations were immeasurably low in all animals that had
    received injections of T3 during the seventh month of the study.
    Serum T3 concentrations in all 3 groups decreased significanlty with
    time; additionally, 4% erythrosine in the diet decreased the T3
    concentration and the values were significantly lower than controls at
    1, 2, 4, and 5 months. The effects of 0.5% erythrosine on T3 levels
    were unclear, significant depressions relative to controls only being
    observed at the 1- and 2-month time periods and not subsequently. In
    animals receiving 4% erythrosine, serum rT3 concentrations increased
    approximately 7-fold and remained elevated throughout the 6 months of
    the study. In both control and 0.5% groups, serum rT3 concentrations
    did not differ significantly from base-line values or from each other.
    Serum rT3 was undetectable in animals receiving injections of T3
    during the final month of the study.

         In vitro metabolism of 125I-labelled T4 was greatly altered
    in liver homogenates from rats fed 4.0% erythrosine in the diet, with
    degradation of T4 decreasing to approximately 40% of values in
    homogenates of control livers. There was an associated decrease of
    about 75% in the generation of 125I-iodide and an approximately 80%
    decrease in the generation of 125I-T3 from 125I-T4. Percentage
    degradation of T4 and generation of iodide and T3 in liver
    homogenates from rats fed 0.5% erythrosine were similar to controls.

         In vitro metabolism of T4 was studied in pituitary glands
    from the control, 1, 2, and 4% dose groups. Overall, 125I-T4
    degradation and generation of 125I-iodide appeared higher in the two
    higher erythrosine dose groups, than in controls, but none of the
    differences were statistically significant.

         The results were interpreted as indicating that the primary
    effect of high doses of erythrosine on thyroid hormones is inhibition
    of type I 5'-monodeiodination of T4 to T3. As a consequence, TSH
    secretory mechanisms were activated in the pituitary. The increases in
    serum rT3 levels were considered to arise from both increased
    availability of the T4 precursor and inhibition of metabolism of
    rT3 by 5'-monodeiodination (Ingbar et al., 1984a).

         In identical studies on female rats to those outlined above,
    similar results were obtained in that erythrosine at dietary
    concentrations of 4% caused an increase in serum T4, rT3, and TSH
    concentrations, a decrease in hepatic deiodination of T4 to T3, and
    an increase in deiodination in the pituitary. Hepatic generation of
    T3 from T4 was also diminished following dietary administration of

    0.5% erythrosine, but to a lesser degree and no changes in serum
    thyroid-related hormones could be detected. No alteration in the
    metabolism of T4 was observed in liver homogenates from rats
    receiving 0.25% dietary erythrosine (Ingbar, 1985).

         In both the above studies, ultrastructural examination of
    thyroids of rats receiving 4% erythrosine in the diet for 6 months
    revealed enhanced synthetic and secretory activity consistent with
    prolonged hyperstimulation by TSH. Less marked changes were seen at
    the 0.5% dose level and the changes generally were less in females
    than males similarly treated (see Special studies on thyroid
    morphology).

         Groups of 13 adult male Sprague-Dawley rats were fed 0, 0.5, 1,0,
    or 4.0% erythrosine in the diet, 100 mg sodium iodide/kg b.w./day, or
    1000 mg fluorescein/kg b.w./day for three weeks. The rats were then
    subjected to an in vivo TSH-releasing hormone (TRH) provocative test
    (100 ng/100 g b.w.). Of all the treatments, only 4% dietary
    erythrosine produced an exaggerated response to TRH; ten minutes after
    TRH injection, the serum TSH levels were 80% greater than controls
    (p < 0.01). Erythrosine also produced a dose-dependent increase in
    total serum T4 levels, significant (p < 0.01) at the 1% and 4% dose
    levels and, at the 4% level, there was also a significant increase in
    serum T3 levels and a significant decrease in T3 resin uptakes.
    The free T4 indices were significantly elevated after treatment with
    1% or 4% dietary erythrosine, but the free T3 indices were not. The
    data were taken to indicate that feeding with 4% erythrosine disrupts
    the normal negative feedback regulatory mechanism of the pituitary-
    thyroid axis and the TRH hyper-responsiveness in the presence of elevated
    serum T4 and T3 levels suggested that the defect did not arise
    from a conventional antithyroid mechanism. The data also suggested that
    the effect of erythrosine on TSH release was due to intact dye or an
    iodinated metabolite rather than to the fluorescein nucleus (Witorsch
    et al., 1984).

         In man, oral administration of 16 mg of erythrosine daily for 10
    days resulted in an increase from 6 to 11 µg of protein-bound iodine
    per 100 ml serum after 15 to 20 days, followed by a sharp decline in
    iodine levels in the next 10 days, with a gradual return to the
    initial value in three months (Anderson et al., 1964).

         Erythrosine could be an adventitious source of iodide (Vought
    et al., 1972).

         No biologically-significant increases in plasma inorganic iodine
    or in urinary iodine were found in 6 patients (aged 25-68 years, sex
    not reported) after oral exposure to 1.9 µmole (1.68 mg/day) of
    erythrosine for 10 days. In other assays of thyroid function, thyroid
    radioiodine uptake, levels of thyroxine, and PBI in plasma remained
    unchanged (Bernstein et al., 1975).

         When cherries coloured with erythrosine are stored in plain cans,
    fluorescein is readily formed by interaction of the tin-iron couple
    that is present. This does not occur in lacquered cans. The production
    of fluorescein from erythrosine occurs in the presence of metallic
    iron and/or tin and free organic acid as a result of electrochemical
    reduction in the can (Dickinson & Raven, 1962).

         It was found that 200-400 mg/l erythrosine inhibited the action
    of pepsin, but had no effect on lipase activity (Diemair & Hauser,
    1951).

         It was also found that this colour had in vivo as well as
    in vitro haemolytic effect. In the in vivo studies the mouse was
    used (Waliszewski, 1952).

         Erythrosine was administered twice weekly to rats in doses of 5,
    10, 15, or 50 mg per rat weighing 200-250 g for 6 months. Haemoglobin
    and red cell counts were reduced at 3 months. The cholesterol levels
    of males were depressed. Excretion of the dye was mainly in unchanged
    form in the faeces (Bowie et al., 1966).

    Toxicological studies

    Special studies on carcinogenicity

    See under long-term studies.

    Special studies on mutagenicity

         Erythrosine was tested for mutagenic activity and showed a very
    slight but statistically-significant mutagenic effect on Escherichia
    coli at a concentration of 0.5 g/100 ml. It was found that the
    xanthene molecule itself was the causative factor and that the
    substituent groups only modify the effect (Luck et al., 1963;
    Luck & Rickerl, 1960).

         No mutagenic activity was observed using E. coli WP2 UVrA as
    the indicator organism (Haveland-Smith & Combes, 1980).

         A lack of mutagenic activity of erythrosine in Salmonella
    typhimurium strains TA98, TA100, TA1535, TA1537, and TA1538 was
    observed when tested in the Ames test at concentrations ranging from 1
    to 10,000 µg/plate with or without metabolic activation (Auletta
    et al., 1977; Bonin & Baker, 1980; Brown et al., 1975).

         Similar negative results in the Ames Test were obtained in
    several other recent studies (Tarján & Kurti, 1982; Ishidate et al.,
    1984; Jaganath & Myth, 1984a; Muzzall & Cook, 1979).

         Erythrosine was inactive in the host-mediated rec-assay
    (Kada et al., 1972) and in a mouse host-mediated assay using
    Salmonella typhimurium strains TA98, TA100, and TA1537 (Tarján &
    Kurti, 1982).

         Erythrosine was found to be non-mutagenic in a mouse lymphoma
    L5178Y TK+/- forward mutation assay (Cifone & Myhr, 1984) and did not
    induce cell transformation in rat embryo cells in vitro or in vivo
    (Price et al., 1978).

         Erythrosine was inactive in DNA-repair, fluctuation, and
    treat-and-plate assays (Haveland-Smith et al., 1981) and in mitotic
    gene conversion assays using yeast strain B234 (Sankaranarayanan &
    Murthy, 1979) and strain D5 (Jaganath & Myhr, 1984b; Matula & Downie,
    1984). Reported positive results in a mitotic gene conversion assay
    using yeast strain D7 (Matula & Downie, 1984) and in a reverse
    mutation assay in yeast XV185-14C have been called into question
    (Brusick, 1984).

         Erythrosine was inactive in the mouse micronucleus assay (Tarján
    & Kurti, 1982; Ivett & Myhr, 1984). An in vitro chromosome
    aberration assay in hamster cells indicated an effect, but this may
    have resulted from osmotic effects of the high concentration (5 mg/ml)
    of erythrosine at which the observations were noted (Ishidate
    et al., 1984).

    Special studies on reproduction

    Rats

         Four groups of Charles River CD rats (23-25 males and
    females/group) received erythrosine in the diet at dose levels of 0,
    0.25, 1.0, or 4.0% for 3 consecutive generations. The F0 parental
    rats received their respective diets for 69 days prior to mating. The
    study showed that during the gestation period slight to moderate
    reductions in mean maternal body-weight gain were noted in females of
    all generations at the 1.0 and 4.0% dose levels. Slight to moderate
    reductions in mean pup body weights were recorded at the 4.0% level on
    lactation days 0, 4, 14, and 21 in all generations. These reductions
    were statistically-significant only on lactation day 21. There were no
    consistent compound-related effects on the reproductive performance of
    males and females and pup survival at any dose level in any generation
    (Albridge et al., 1981).

         Groups of 18-22 pairs (males and females, weighing 200-220 g) of
    adult Sprague-Dawley rats were fed diets containing erythrosine at
    levels of 0, 0.25, 0.5, or 1.0% for 2 weeks before mating and during
    the mating period. The diets were continued for the females throughout
    gestation and lactation and were provided continuously to their

    offspring until they reached 90-100 days. Animals in the positive
    control group did not receive erythrosine in the diet, but offspring
    were injected daily with 50 mg/kg of hydroxyurea on post-natal days
    2-10. Two years later, a second experiment, a replication of the first
    one with the same dose groups and number of animals per group was
    performed. In both experiments, parental animals were evaluated for
    weight and food consumption and females for reproductive success. The
    offspring were assessed for behavioural toxicity plus weight, food
    consumption, physical development, and brain weight.

         Erythrosine produced no reductions in parental or offspring
    weight or food consumption. Erythrosine significantly increased
    pre-weaning offspring mortality at the 0.5 and 1.0% dose levels in the
    first experiment, but not in the second. Mean litter size was not
    adversely affected by erythrosine in either experiment. Behaviourally,
    erythrosine produced no dose-dependent effects that replicated across
    the two experiments. The authors concluded that these studies provided
    no evidence that erythrosine, via dietary exposure at levels as high
    as 1.0%, is psychotoxic to developing rats (Vorhees et al., 1983).

    Special studies on thyroid morphology

         Thyroid glands from the Primate Research Institute 27-week
    toxicity study (see Couch et al., 1983 study under Long-term
    studies) were subjected to ultra-structural examination by electron
    microscopy. Rats fed erythrosine were reported as displaying
    hypertrophy of follicular cells with increased development of
    synthetic and secretory organelles (rough endoplasmic reticulum, Golgi
    apparatuses, and long microvilli). These changes were interpreted as
    representing mild to moderate stimulation of follicular cells
    consistent with elevated serum T4 levels. Lysosomal bodies in rats
    receiving erythrosine were described as being larger, more irregular,
    and electron dense than controls and appeared to be closely associated
    or fused with the limiting membrane of colloid droplets, a process
    involved in secretion of thyroid hormones. The degree of thyroid
    stimulation and the accumulation of colloid droplets and lysosomes in
    follicular cells were stated to be greater in male than in female rats
    fed commercial erythrosine. Ultrastructural indications of long-term
    thyroid stimulation appeared greater in rats fed commercial
    erythrosine than in rats fed purified colour with supplemental iodide
    (Capen, sine data a).

         Thyroids from rats fed 0, 0.25, 0.5, or 4,0% erythrosine in a
    7-month study of thyroid function (see Ingbar et al., 1984 study
    under Biochemical aspects) were subjected to examination by electron
    microscopy. Thyroid follicular cells from rats fed erythrosine were
    reported as displaying ultra-structural features of a dose-dependent
    stimulation of synthetic and secretory activity, most marked in rats
    fed 4% erythrosine and indicated by hypertrophy of follicular cells

    with increased development of secretory organelles. These features
    were considered to be generally consistent with a response to
    long-standing TSH stimulation. The ultrastructural changes were
    reversible by administration of T3 during the last month. A
    dose-dependent accumulation of numerous lysosome-like bodies observed
    in follicular cells of treated rats were considered not to be an
    expected response to TSH stimulation alone. Similar, but less marked
    changes, in follicular cell stimulation and accumulation of
    lysosome-like bodies were stated to be present in rats fed erythrosine
    at dietary levels of 0.25 and 0.5% (Capen, sine data b).

    Acute toxicity

                                                                        

                            LD50
    Animal      Route       (mg/kg b.w.)      Reference
                                                                        

    Mouse       Oral           6800           Butterworth et al., 1976a
                i.p.            360           Butterworth et al., 1976a
                i.v.            370           Waliszewski, 1952

    Rat         Oral           1895           Lu & Lavallee, 1964
                               7100           Butterworth et al., 1976a
                               1840           Hansen et al., 1973a
                i.p.            300           Emerson & Anderson, 1934
                                350           Butterworth et al., 1976a

    Gerbil      Oral           1930           U.S. FDA, 1969

    Rabbit      i.v.            200           Emerson & Anderson, 1934
                                                                        

         A group of 5 young rats was given s.c. injections twice daily of
    250 mg erythrosine/kg b.w. in aqueous solution for 3 days. The rats
    were killed on the fourth day. No oestrogenic activity (based on the
    observation that uterine weights were normal) was detected (Graham &
    Allmark, 1959).

         In experiments with guinea-pigs, it was found that erythrosine
    had no sensitization activity (Bär & Griepentrog, 1960).

    Short-term studies

    Rats

         In a 90-day study on 5 groups of 15 male and 15 female rats,
    erythrosine was given at levels of 0, 0.25, 0.5, 1, or 2% of the diet.
    No adverse effects were noted as regards body weight, food intake,
    haematology, or blood and urine analyses which could be related to
    administration of the test substance. Organ weights were normal except
    that absolute and relative caecal weights were higher at all levels
    tested. Caecal enlargement was dose-related, but histology was normal.
    Absolute and relative thyroid weights were increased at the 2% level.
    Histopathology showed no abnormalities except pigment deposition in
    renal tubules in females at the 2% level and in males at all levels in
    a dose-related manner. The pigment was identified as protein-bound
    erythrosine. In addition, total PHI and protein-bound erythrosine in
    serum were raised at all levels in a dose-related manner, and non
    protein-bound iodine increased with dose levels. However, T4 iodine
    remained unchanged and 131I uptake was reduced (Hansen et al.,
    1973b).

         Five groups of Carworth farm E strain SPF rats (15 males and 15
    females/group) received 0, 0.25, 0.5, 1.0, or 2.01 erythrosine in the
    diet for 90 days. There were no effects attributable to treatment on
    the rate of body-weight gain or food intake or on the results of
    haematological examinations, serum analyses, or renal function tests.
    Thyroid weight relative to body weight was slightly increased in rats
    receiving 1.0 and 2.0% erythrosine. Thyroid activity was not impaired
    at any dietary level of erythrosine. This was indicated by the normal
    histopathology of the organ, the lack of effect on serum T4 levels,
    and the normal rates of oxygen consumption in the treated animals
    (Butterworth et al., 1976a).

         Groups of Sprague-Dawley female rats (12-20 animals per group)
    were exposed to erythrosine in the diet at dose levels of 0 or 0.2%
    for either 6 or 12 months. During the last 12 weeks of the
    experimental period, a slight decrease of body-weight gain was
    observed in rats exposed for 12 months. Other parameters such as food
    consumption, haematology, clinical chemistry, urinalysis, and organ
    weights were comparable among treated and control rats in both the
    6-and 12-month groups. Sporadic pathological changes were observed in
    treated and control rats (Sekigawa et al., 1978).

    Gerbils

         Three groups of gerbils (15 males and 15 females/group) received
    erythrosine in the diet at dose levels of 200, 750, or 900 mg/kg for
    19 months (those animals in the 900 mg/kg dosage group received
    1200 mg/kg for the first 3 months). The control group consisted of 30
    males and 30 females. Body-weight decreases were seen in male gerbils

    at all feeding levels. However, this weight loss was observed in
    females only at the 900 mg/kg level. Elevated PBIs, due to
    interference by erythrosine with PBI determinations, were seen. No
    other haematological differences were seen. No adverse gross pathology
    was noted. Histopathology was not performed (U.S. FDA, 1969).

    Dogs

         Two-year feeding studies were conducted with groups of 3 male and
    3 female beagle dogs at levels of 0, 0.5, 1.0, or 2.01 erythrosine in
    the diet. All dogs survived the study. No gross or microscopic
    pathological changes related to colour administration were observed
    (Hansen et al., 1973b).

    Pigs

         Four groups of large white strain pigs (3 males and 3 females/
    group weighing approximately 20 kg each) were fed erythrosine
    in their diets at dose levels of 0, 167, 500, or 1500 mg/kg b.w./day
    for 14 weeks. The treated pigs exhibited decreased levels of serum
    T4 when compared with controls. There were dose-related increases in
    the serum levels of PBI, non-protein-bound iodine, and protein-bound
    erythrosine in animals of all trated groups. A dose- related increase
    in thyroid weight was noted, although the differences were
    statistically-significant only in female pigs at the higher-dose
    levels (500 and 1500 mg/kg b.w./day) when compared with the controls.
    None of the treated pigs revealed pathological changes of the thyroid
    (Butterworth et al., 1976b).

    Long-term studies

    Mice

         A total of 122 male and female mice aged 50-100 days produced by
    mixed breeding from five different strains were given a diet
    containing 1 mg of the colour per animal per day. A negative control
    group consisting of 168 mice and two positive control groups, which
    were given alpha-aminotoluene and dimethylaminoazobenzene, were also
    included. A number of the animals were sacrificed after an observation
    period of 500 days and the remaining mice were killed after 700 days.
    The formation of liver tumours was noted in animals in the positive
    control groups after approximately 200 days. The incidence of tumours
    in mice receiving the colour was not significantly greater than in the
    negative controls (Waterman & Lignac, 1958).

         Chronic feeding studies were conducted with mice. Seventy mice
    were fed erythrosine at 1 or 2%. Because of the small number of
    animals surviving the experiment and the small number of tumours
    found, no effect on tumour formation could be attributed to the colour
    (U.S. FDA, 1969).

         Five groups of Charles River CD-1 mice (60 males and 60
    females/group) were exposed to erythrosine in the diet at dose levels
    of 0 (2 control groups were used), 0.3, 1.0, or 3.0% for 24 months.
    The respective average consumption of erythrosine was 0, 424, 1474, or
    4759 mg/kg b.w./day for males and 0, 507, 1834, or 5779 mg/kg b.w./day
    for females. With the exception of significantly-decreased body
    weights (throughout the entire study) of males and females at the 3.0%
    dose level, other investigated parameters (mortality, food intake,
    haematology, gross pathology, and histopathology) were not adversely
    affected by erythrosine treatment at any dose level (Richter et al.,
    1981).

         Two groups of 7-week old ICR mice weighing 27-38 g (50 males and
    50 females/group) were fed diets containing erythrosine at dose levels
    of 1.25 or 2.5% for 18 months. The mice received erythrosine in cube
    diet for the first 20 weeks, and thereafter the erythrosine was mixed
    with the basic powder diet. All animals in the experimental groups
    were fed the basic diet free of erythrosine for an additional 6
    months, after which they were sacrificed and autopsied. The control
    group consisted of 45 males and 45 females. Mortality was greater
    among animals exposed to erythrosine than among the controls
    (approximately 61% of the animals died in the 2.5% group, 59% in the
    1.25% group, and 36% in the control group). Body-weight gains were not
    adversely affected by erythrosine ingestion. Animals in both
    experimental groups exhibited a high incidence of lymphocytic
    leukemia, and sporadic cases of pulmonary adenomas were observed. The
    frequency of both lesions was in the range spontaneously-occurring in
    this strain of mice. The results indicate that erythrosine was not
    carcinogenic to ICR mice under the experimental conditions utilized
    (Yoshii & Isaka, 1984).

    Rats

         Groups of 24 weanling rats, evenly divided by sex, were fed
    erythrosine at 0, 0.5, 1.0, 2.0, or 5.0% for 2 years. Slight growth
    depression was observed in the animals at the 5% level. Those animals
    fed more than 0.5% erythrosine had distended caeca, but
    microscopically the distended caeca showed normal histology. The
    statistical evaluation of the rat study revealed no significant
    changes in organ weights at the highest level. There was some
    diarrhoea at the 5% level. There were no differences in survival among
    the test groups (U.S. FDA, 1969).

         Erythrosine was fed at a level of 4% of the diet to 5 male and
    female rats for periods up to 18 months. Gross staining was observed
    in the glandular stomach and small intestine, and granular deposits
    were observed in the stomach, small intestine, and colon. Hepatic
    cirrhosis was noted in 1 out of 4 rats living up to 12 months. Fifty
    control animals observed for 20 months or more failed to develop
    tumours or hepatic cirrhosis (Willheim & Ivy, 1953).

         Groups of 12 male and 12 female weanling Osborne-Mendel rats were
    fed 0, 0.5, 1.0, 2.0, or 5.0% erythrosine in their diet for two years.
    Growth depress ion was observed in rats given 5% erythrosine. The
    relative spleen weight was depressed in all male test groups and in
    females at the 5% level. Slight caecal enlargement was noted at 1%,
    which increased with dose, but the histology of the enlarged caeca was
    normal. No other gross or hispathological findings related to colour
    administration were noted (Hansen et al., 1973b).

         Groups of 2.5 male and 25 female 100-day old rats and groups of
    50 male and 50 female control rats were fed 0, 0.5, 1.0, 2.0, or 4.0%
    erythrosine in their diets for 86 weeks. Other groups of 25 male and
    25 female rats aged 100 days were intubated twice a week for 85 weeks
    with 0, 100, 235, 750, or 1500 mg erythrosine/kg b.w. After this
    treatment, the animals were kept on normal diets for the remainder of
    the two years of the study. Body-weight decreases were seen at the 2
    and 4% levels. Elevated PBI, due to interference by erythrosine with
    PBI determinations rather than due to thyroid dysfunction, were seen.
    T4 iodine levels were not affected. There were no other
    haematological differences and no anaemia was seen. No adverse gross
    pathology was noted; histopathology examinations did not show any
    colour-related abnormalities (Hansen et al., 1973b).

         Groups of 70 male and 70 female Charles River CD weanling rats
    were fed erythrosine in the diet at levels of 0.1, 0.5, or 1.0% for 30
    months after in utero exposure. Two concurrent control groups
    (70 animals/sex/group) received no colour in the diet. The respective
    average consumption of erythrosine was 49, 251, or 507 mg/kg b.w./day
    for males and 61, 307, or 642 mg/kg b.w./day for females. There were
    no consistent significant compound-related effects during the
    in utero phase. In the main study, there were no consistent
    significant compound-related effects on the following: physical
    observation, behaviour, mortality, food consumption, haematology,
    clinical chemistry, urinalysis, or ophthalmological findings. Mean
    body weights of control and treated rats did not differ significantly
    during the exposure period. The gross pathological changes that were
    noted could not be attributed to treatment with erythrosine. The
    incidence of non-neoplastic lesions was comparable between treated and
    control groups. There was a statistically-significant increase in the
    incidence of benign thyroid tumours (follicular adenomas): 6/68 in the
    1.0% female test group versus 0/140 in the control group. The
    incidence of malignant tumours in rats of treated groups was
    comparable with that of the controls (Brewer et al., 1981).

         Two groups of Charles River CD weanling rats (70 males and 70
    females/group) were given erythrosine in the diet at dose levels of 0
    or 4.0% for a period of approximately 29 months after in utero
    exposure. The average consumption of the erythrosine was 2465 mg/kg
    b.w./day for males and 3029 mg/kg b.w./day for females. There were no
    consistent significant compound-related effects on the following;

    physical observations, behaviour, mortality, food consumption,
    haematology, clinical chemistry, urinalysis, or ophthalmological
    findings. Mean body weights of treated rats (both sexes) were slightly
    lower throughout the study than those of the control rats. These
    differences were statistically-significant except at weeks 3-5 and 122
    (males) and at weeks 0-4, 6, and 114 (females). The mean absolute and
    relative thyroid weights of treated males were more than twice those
    of the controls. Histopathological examination revealed that the
    incidence of thyroid hyperplasia (follicular and C-cell) was
    significantly increased in treated males. There was a statistically-
    significant increase in the incidence of follicular adenoma of the
    thyroid in treated male rats (16/68) when compared with the controls
    (0/69). The incidence of malignant tumours, including thyroid C-cell
    and follicular carcinomas, was comparable among treated and control
    rats (Brewer et al., 1982).

         Groups of 6-week-old pathogen-free F344 rats (50 males and 50
    females) were fed diets containing erythrosine at levels of 1.25 or
    2.5% for 18 months. The control group consisted of 30 males and 30
    females that received a diet free of erythrosine. For the first 20
    weeks of treatment, erythrosine was given in pelleted diet and for the
    remaining treatment period it was given in powder diet. Rats exposed
    to erythrosine were sacrificed 18 months, and the control rats 24
    months, after the start of the study. No parameters other than
    histopathology were reported. Histopathological examinations revealed
    sporadic cases of spontaneous neoplasms (tumours of the genital
    system, endocrine system, haematopoietic system, and digestive
    system), but their frequencies were similar among animals in the
    erythrosine-treated groups and they were comparable to the controls.
    No pathological changes were observed in the thyroid glands
    (Fukunishi et al., 1984).

         A study was undertaken to investigate whether the thyroid tumours
    found after chronic feeding of erythrosine to male rats at a dose
    level of 4.0% in the diet resulted from excess iodine (either as a
    contaminant of the colour or as iodine metabolized from the colour) or
    from another non-iodine-related property of erythrosine. The study was
    composed of the following six dose groups, each containing 70
    (35 males and 35 females) Charles River CD rats, with continuous
    exposure for 27 weeks:

               Group 1 -   unadulterated diet.

               Group 2 -   80 µg of NaI (sodium iodide)/g of diet.

               Group 3 -   purified erythrosine at 4.0% in the diet.

               Group 4 -   purified erythrosine at 4.0% in the diet plus
                           80 µg of NaI/g of diet.

               Group 5 -   purified erythrosine at 4.0% in the diet plus
                           160 µg of NaI/g of diet.

               Group 6 -   commercial erythrosine at 4.0% in the diet.

         The feeding of commercial erythrosine at a level of 4% in the
    diet produced hyperthyroidism. TSH and T4 were elevated, while T3
    concentrations were depressed. Changes in clinical chemistry
    parameters, body weight, and food consumption were also indicative of
    hyperthyroidism. Additional purification of the commercial preparation
    of erythrosine to remove free iodide did not modify these effects.
    These responses were not found after feeding a diet spiked with NaI
    only. This study demonstrated that thyroid changes observed in this
    and former studies are associated with increased TSH concentrations.
    However, the mechanism for these effects of erythrosine cannot be
    determined from the results of this study (Couch et al., 1983).

         Twenty rats were subject to weekly s.c. injections of 1 ml of a
    5% aqueous solution of erythrosine for 596 days (85 weeks). The total
    quantity of colour administered was 2.65 g/animal. Seven rats survived
    300 days or more. No tumours were observed (Umeda, 1956).

         Eighteen rats were injected s.c. with aqueous solutions of
    erythrosine at 12 mg/animal once per week for 2 years. No tumours
    either at the injection sites or in other parts of the body were
    observed (Hansen et al., 1973b).

    Gerbils

         Three groups (15-16 animals/sex/group) of Mongolian gerbils,
    approximately 6 months old, were fed diets containing erythrosine at
    levels of 1.0, 2.0, or 4.0% for 105 weeks. Control groups (31 animals
    of each sex) were fed diets free of erythrosine. Animals of all
    treated groups exhibited a statistically-significant dose-related
    decrease in body-weight gain when compared with the controls. In
    general, there were slight, and in some isolated cases significant,
    depressions of haematocrit and haemoglobin values and leucocyte and
    reticulocyte counts in animals of treated groups. The relative weights
    of heart, liver, and spleen were significantly decreased in animals of
    both sexes at the two high-dose levels. Dose-related changes such as
    enlargement of follicles and, in some cases focal hyperplasia, were
    observed in the thyroids of treated animals. Histopathology did not
    reveal any treatment-related effects (Collins & Long, 1976).

         Groups of 20-24 male and Mongolian gerbils approximately 6 months
    old received erythrosine (dissolved in water) by stomach intubation at
    dose levels of 200, 750, or 900 mg/kg twice weekly for 97 weeks. A
    control group (32 animals/sex) was intubated with distilled water
    only. The dosages were administered in a volume of 10 ml/kg b.w. No

    treatment-related adverse effects were observed for investigated
    parameters such as clinical toxicity, mortality, body-weight gain,
    haematology, organ weights, gross pathology, or histopathology
    (Collins & Long, 1976).

    Observations in man

         Five human volunteers (four males and one female, aged
    21-35 years) received erythrosine in the diet at dose levels of 5, 10,
    or 25 mg/day in weekly increments for a period of 3 weeks. Total serum
    iodine and PBI increased slowly and slightly in association with the
    weekly increasing erythrosine doses. Other tests for serum T4, T3,
    TSH, erythrosine, urinary iodine, erythrosine excretion, and
    T3-resin uptake remained unchanged throughout the 3 weeks. Increases
    in serum PBI and total serum iodine during the exposure period
    indicates that a portion of the iodine ingested as erythrosine appears
    to be absorbed from the gastrointestinal tract. No changes in
    concentration of TSH, T4, and T3 in serum indicate that both the
    thyroid function and thyroregulatory mechanisms were unaffected by the
    ingestion of erythrosine during a three-week period at dose levels of
    5, 10 and 25 mg/day in weekly increments (Ingbar et al., 1983).

         Human volunteers were given single doses of 75-80 mg erythrosine
    labelled with 131I in a milk-shake or lemonade; the subjects
    received a daily dose of 5 drops of saturated potassium iodide
    solution to block thyroid uptake of 131I. Whole-body counts were
    carried out and complete stool and urine samples were examined for
    activity; daily blood samples were also examined for total serum
    131I, and for T4 and T3.

         Faecal excretion of 131I approximated 100% in four subjects; in
    two subjects, lower recoveries (80 and 90%) were achieved, but this
    was probably due to incomplete collection, as the unrecovered activity
    was not detectable in whole-body counts, urinary 131I, or serum.
    Urinary excretion of label in 48 hours did not exceed 0.38% of the
    dose in any subject and the urinary counts after 48 hours were similar
    to background. Whole-body counts indicated that 131I-erythrosine was
    eliminated rapidly and nearly completely, less than 1% of the
    administered dose remaining after 7 days. The small amount of
    remaining activity declined exponentially in the period from 7-14 days
    after administration, with the half-life averaging 8.4 ± 2.1 days.
    Extrapolation of this slow phase to zero time indicated a potential
    initial body retention of 1.2 ± 0.4% of the administered dose.
    Negligible quantities of 131I appeared in the serum, never exceeding
    0.013% of the dose/l serum, and in none of the studies were the serum
    T4 and T3 concentrations significantly altered following ingestion
    of erythrosine.

         These studies indicate that only a small proportion of ingested
    erythrosine is absorbed from the gastrointestinal tract of man and, at
    the single oral dose levels used, erythrosine did not affect thyroid
    hormone levels (Ingbar et al., 1984b).

    Comments

         Further metabolic studies confirmed that erythrosine is only
    absorbed to only a small extent from the gastrointestinal tract in
    rats and man. Biochemical studies of thyroid function and of
    metabolism of thyroid hormones in the liver and pituitary indicate
    that erythrosine inhibits deiodination of T4 to T3 and,
    consequently, at high dose levels, activates TSH secretory mechanisms
    in the pituitary.

         Morphological changes in the thyroid follicular cells induced by
    prolonged exposure to high doses of erythrosine were reported to be
    consistent with stimulation of synthetic and excretory processes and
    to support the view that the development of thyroid tumours in
    long-term studies in rats might be mediated by a hormonal effect. The
    morphological changes were reported to be reversible by administration
    of T3, even in rats continuing to be exposed to 4% erythrosine in
    the diet, further supporting a hormonal mechanism.

         Additional studies on the mutagenicity of erythrosine confirm
    that it is non-genotoxic. No effects on thyroid function or regulatory
    mechanisms were observed in human studies at dose levels up to 80 mg
    (single dose) or in a three-week study in which erythrosine was
    administered in incrementally-increased doses of 5, 10, and 25 mg
    daily for 7 days.

    EVALUATION

    Level causing no toxicological effect

         Rat:      0.25% in the diet, equivalent to 125 mg/kg b.w./day

    (based on studies of biochemical effects on thyroid hormone metabolism
    and regulation).

    Estimate of temporary acceptable daily intake for man

         0-0.6 mg/kg b.w.

    Further work or information

    Required (by 1988)

         Parmacokinetic studies on erythrosine relating the amount of
    absorption to the amount ingested, which would enable a correlation to
    be established between blood/tissue levels of erythrosine and effects
    on the thyroid.

    REFERENCES

    Albridge, D., Schardein, J.L., Blair, M., Goldenthal, E.I., &
         Benson, B.W. (1981).  Three generation reproduction study.
         Unpublished report from International Research and Development
         Corporation, Mattawan, MI, USA. Submitted to WHO by the Certified
         Color Manufacturers Association, Inc., Washington, DC, USA.

    Andersen, C.J., Keiding, N.R., & Nielson, A.B. (1964). False elevation
         of serum protein-bound-iodine caused by red colored drugs or
         foods. Scand. J. Clin. Lab. Invest., 16, 249.

    Auletta, A.E., Kuzava, J.M., & Parmar, A.S. (1977). Lack of mutagenic
         activity of a series of food dyes for Salmonella typhimurium.
         Mutat. Res., 56, 203.

    Bär, F. & Griepentrog, F. (1960). Die Allergenwirkung von Frenden
         Stoffen in den Lebensmitteln. Med. U. Ernahr, 1, 99-104.

    Bernstein, R., Haugen, H.F., & Frey, H. (1975). Thyroid function
         during erythrosine ingestion in doses encountered in therapy with
         conventional antibiotics. Scand. J. Clin. Lab. Invest., 35, 49.

    Bonin, A.M. & Baker, R.S.U. (1980). Mutagenicity testing of some
         approved food additives with Salmonella microsome assay.
         Fd. Tech. Aust., 32, 608.

    Bowie, W.C., Wallace, W.C., & Lindstrom, H.V. (1966). Some clinical
         manifestations of erythrosine in rats. Fed. Proc.,
         25, 556 (Abstract 2079).

    Brewer, L., Jefferson, N.D., Blair, M., Thorstenson, J.B.,
         Nair, K.P.C., Richter, W.R., Keller, W.F., Goldenthal, E.I., &
         Benson, B.W. (1981). Long term dietary toxicity/carcinogenicity
         study in rats. Unpublished report No. 410-002 from International
         Research and Development Corporation, Mattawan, MI, USA.
         Submitted to WHO by the Certified Color Manufacturers Association
         Inc., Washington, DC, USA.

    Brewer, L., Jefferson, N.D., Blair, M., Thorstenson, J.B.,
         Nair, K.P.C., Richter, W.R., Keller, W.F., Goldenthal, E.I., &
         Benson, B.W. (1982). Long term dietary toxicity/carcinogenicity
         study in rats. Unpublished report No. 410-011 from International
         Research and Development Corporation, Mattawan, MI, USA.
         Submitted to WHO by the Certified Color Manufacturers Association
         Inc., Washington, DC, USA.

    Brusick, D.J. (1984). An evaluation of the genotoxicity of erythrosine
         (FD&C Red No. 3). Report to the Certified Color Manufacturers
         Association, Inc. Submitted to WHO by the Certified Color
         Manufacturers Association, Inc., Washington, DC, USA.

    Brown, J.P., Roehm, G.W., & Brown, R.J. (1978). Mutagenicity testing
         of certified food colours and related azo, xanthene and
         triphenylmethane dyes with Salmonella microsome system.
         Mutat. Res., 56, 249.

    Butterworth, K.R., Gaunt, I.F., Grasso, P., & Gangolli, S.D. (1976a).
         Acute and short-term toxicity studies on erythrosine BS in
         rodents. Fd. Cosmet. Toxicol., 14, 525-531.

    Butterworth, K.R., Gaunt, I.F., Grasso, P., & Gangolli, S.D. (1976b).
         Short-term toxicity of erythrosine BS in pigs. Fd. Cosmet.
         Toxicol., 14, 533-536.

    Capen, C.C. (sine data a). Ultrastructural evaluation of rat thyroid
         gland from Primate Research Institute (PRI), Mew Mexico State
         University, USA. Study No. Cm-70r: Endocrine evaluation of the
         thyroidal effects of FD&C Red No. 3. Report to the Certified
         Color Manufacturers Association, Inc. Submitted to WHO by the
         Certified Color Manufacturers Association, Inc.,
         Washington, DC, USA.

    Capen, C.C. (sine data b). Untitled report to the Certified Color
         Manufacturers Association, Inc. Submitted to WHO by the Certified
         Color Manufacturers Association, Inc., Washington, DC, USA.

    Cifone, M.A. & Myhr, B.C. (1984). Mutagenicity evaluation of 21373-9-2
         in the mouse lymphoma forward mutation assay. Litton Bionetics
         report, August 1984 to Xerox Corp. Submitted to WHO by the
         Certified Color Manufacters Association, Inc.,
         Washington, DC, USA.

    Collins, T.F.X. & Long, E.L. (1976). Effects of chronic oral
         administration of erythrosine in the mongolian gerbils.
         Fd. Cosmet. Toxicol., 14, 233-248.

    Couch, R.C., Hobson, W.C., Selim, S., Eason, R.L., Cummins, L.B.,
         Cadwallader, J., & Helton, E.D. (1983). An endocrine evaluation
         of the thyroidal effects of FD&C Red No. 3. Unpublished report
         from Primate Research Institute, New Mexico State University,
         USA. Submitted to WHO by the Certified Color Manufacturers
         Association, Inc., Washington, DC, USA.

    Daniel, J.W. (1972). The excretion and metabolism of edible food
         colours. Toxicol. Appl. Pharmacol., 4, 572-594.

    Dickinson, D. & Raven, T.W. (1962). Stability of erythrosine in
         artificially coloured canned cherries. J. Sci. Food. Agric.,
         13, 650-652.

    Diemair, W. & Hausser, H. (1951). Synthetic dyes and enzyme reactions.
         Z. Lebensm.-Untersuch. u.-Forsch., 92, 165-170.

    Emerson, G.A. & Anderson, H.H. (1934). Toxicity of certain proposed
         anti-leprosy dyes: fluorescein, eosin, erythrosine, and others.
         Int. J. Leprosy, 2, 257-263.

    Fukunishi, R., Mori, B., Yoshida, B., Yoshida, A., Kadota, A., &
         Hamakawa H. (1984). Carcinogenicity study of erythrosine (FD&C
         Red No. 3) in F344 rats. In press: Fd. Chem. Toxicol.

    Garber, J., Ruiz, M., Iflah, S., Gluckin, D., & Ingbar, S.H. (1981).
         Effects of erythrosine (2',4',5',7'-tetraiodofluorescein;
         red dye 3) on aspects of thyroid economy in rats and man. Program
         of the 63rd Annual Meeting of the Endocrine Society,
         Cincinatti, OH, USA. Abstract 439, p. 19.

    Graham, R.C.B. & Allmark, M.G. (1959). Screening of some food colors
         for estrogenic activity. Toxicol. Appl. Pharmacol., 1, 144-146.

    Hansen, W.H., Davis, K.J., Graham, S.L., Perry, C.H., & Jacobson, K.H.
         (1973a). Long-term toxicity studies of erythrosine. II. Effects
         on haematology and thyrosine and protein-bound iodine in rats.
         Fd. Cosmet. Toxicol., 11, 535-545.

    Hansen, W.H., Zwickey, R.E., Brouwer, J.B., & Fitzhugh, O.G. (1973b).
         Long-term toxicity studies of erythrosine. I. Effects in rats and
         dogs. Pd. Cosmet. Toxicol., 11, 527-534.

    Haveland-Smith R.B. & Combes, R.D. (1980). Screening of food dyes for
         genotoxic activity. Fd. Cosmet. Toxicol., 18, 215-221.

    Haveland-Smith, R.B., Combes, R.D., & Bridges, B.A. (1981). Studies on
         the genotoxicity of some fluorescein dyes. Mutat. Res., 88, 1.

    Ingbar, S.H., Garber, J., & Gluckin, D. (1983). Studies on the
         bio-availability and metabolism of ingested erythrosine in man.
         Draft manuscript. Summary in: A consideration of the data
         relating to the thyroid effects of FD&C Red No. 3. Unpublished
         document submitted to WHO by the Certified Color Manufacturers
         Association, Inc., Washington, DC, USA.

    Ingbar, S.H., Ballman, A., & Braverman, L.E. (1984a). Studies of the
         effects of chronic erythrosine feeding on various aspects of
         thyroid hormone economy in rats. Reports submitted to WHO by the
         Certified Color Manufacturers Association, Inc., Washington,
         DC, USA.

    Ingbar, S.H., Garber, J., & Burrows, B.A. (1984b). Further studies on
         the absorption and metabolism of ingested erythrosine in man.
         Unpublished report submitted to WHO by the Certified Color
         Manufacturers Association, Inc., Washington, DC, USA.

    Ingbar, S.H. (1985). The effects of chronic feeding of erythrosine on
         thyroid hormone economy in female rats. Report submitted to WHO
         by the Certified Color Manufacturers Association, Inc.,
         Washington, DC, USA.

    Ishidate, M., Sofuni, T., Yoshikawa, K., Hayashi, M., Nohmi, T.,
         Sawada, M., & Matsuoka, A. (1984). Primary mutagenicity screening
         of food additives currently used in Japan. Fd. Chem. Toxicol.,
         22, 623-626.

    Ivett. J.L. & Myhr, B.C. (1984). Mutagenicity evaluation of 21373-9-2
         in the in vivo micronucleus assay. Litton Bionetics report, May
         1984, to Xerox Corp. Submitted to WHO by the Certified Color
         Manufacturers Association, Inc., Washington, DC, USA.

    Jaganath, D.R. & Myhr, B.C. (1984a). Mutagenicity evaluation of
         21373-9-2 in the Ames Salmonella/microsome plate test. Litton
         Bionetics report, May 1984, to Xerox Corp. Submitted to WHO by
         the Certified Color Manufacturers Association, Inc.,
         Washington, DC, USA.

    Jaganath, D.R. & Myhr, B.C. (1984b). Mutagenicity evaluation of
         21373-9-2 in mitotic recombination assay with the yeast strain
         D5. Litton Bionetics report, June 1984, to Xerox Corp. Submitted
         to WHO by the Certified Color Manufacturers Association, Inc.,
         Washington, DC, USA.

    Kada, T., Tutikawa, K., & Sadale, Y. (1972). In vitro and
         host-mediated "rec assay" procedures for screening chemical
         mutagens; and ploxine, a mutagenic red dye detected.
         Mutat. Res., 16, 165.

    Lu, F.C. & Lavallee, A. (1964). The acute toxicity of some synthetic
         colours used in drugs and foods. Canad. Pharm. J., 97, 30.

    Lück, R. & Rickerl, E. (1960). Lebensmittelzusatzstoffe und mutagene
         Wirkung (Food additives and mutagenic effect). VI Report.
         Z. Lebensmitt.-Untersuch., 112, 157-174.

    Lück, H., Wallnofer, P., & Bach. H. (1963). Lebensmittelzusatzstoffe
         und mutagene Wirkung. VII. Mittellung. Prufung einiger
         Xanthen-Farbstoffe auf mutagene Wirkung an E. coli. Path.
         Microbiol., 26, 206-224.

    Marignan, R., Boucard, M., & Gelis, C. (1965). Influence possible de
         l'érythrosine sur le métabolisme thyroďdien. Trav. Soc. Pharm.,
         (Montpellier) 24, 127-130.

    Matula, T.I. & Downie, R.H. (1984). Genetic toxicity of erythrosine in
         yeast. Mutat. Res., 138, 153-156.

    Muzzall, J.M. & Cook, W.L. (1979). Mutagenicity of dyes used in
         cosmetics with the Salmonella/mammalian-microsome test.
         Mutat. Res., 67, 1-8.

    Obrist, J., LeVan, L., Puhl, R.J., & Duan, R.J. (1986). Final report:
         Metabolism of FD&C Red No. 3 in rats, study No. 6145-100.
         Unpublished report by Bazleton Laboratories America, Inc.,
         Madison, WI, USA. Submitted to WHO by the Certified Color
         Manufacturers Association, Inc., Washington, DC, USA.

    Price, P.J. Suk, W.A., Freeman. A.E., Lane, W.T., Peters, R.L.,
         Vernon, M.L., & Huebner, R.J. (1978). In vitro and in vivo
         indications of the carcinogenicity and toxicity of food dyes.
         Int. O. Cancer, 21, 361-367.

    Richter, W.R., Nair, K.P.C., Goldenthal, E.I., & Benson, B.W. (1981).
         Long-term  toxicity/carcinogenicity  study  in mice. Unpublished
         report No. 410-005 from International Research and Development
         Corporation, Matrawan, MI, USA. Submitted to WHO by the Certified
         Color Manufacturers Association, Inc., Washington, DC, USA.

    Ruiz, M. & Ingbar, S.H. (1982). Effect of erythrosine
         (2',4',5',7'-tetraiodofluorescein) on the metabolism of thyroxine
         in rat liver. Endocrinology, 110, 1613-1617.

    Sankaranarayanan, N. & Murthy, M.S.S. (1979). Testing of some
         permitted food colours for the induction of gene conversion in
         diploid yeast. Mutat. Res., 67, 309-314.

    Sekigawa, S., Shimomura, H., Yamamoto, H., Okuyama, T., & Tsubura, Y.
         (1978). Additive toxicity of Food Red No. 2 and No. 3 in rats.
         J. Nara Med. Ass., 29, 709.

    Tarján, V. & Kurti, M. (1982). Mutagenicity testing of several food
         colourants certified for use in Hungary. Mutat. Res., 97, 228.

    Umeda, M. (1956). Experimental study of xanthene dyes as carcinogenic
         agents. Gann, 47, 51-78.

    U.S. FDA (1969). Studies attributed to the United States Food and Drug
         Administration as an unpublished report. Reference and summary
         reported in WHO Food Additives Series No. 6, p. 80 (Annex 1,
         reference 36).

    Vorhees, C.V., Butcher, R.E., Brunner, R.L., Wootten, V., & Sobotka,
         T.J. (1983). A developmental toxicity and psychotoxicity
         evaluation of FD&C Red Dye No. 3 (erythrosine) in rats.
         Arch. Toxicol., 53, 253.

    Vought, R.L., Brown, F.A., & Wolfe, J. (1972). Erythrosine: an
         adventitious source of iodine. J. Clin. Endocr. Met.,
         34, 747-752.

    Waliszewski, T. (1952). Chromatographic and biological investigations
         of food stuff colouring matters (in Polish). Acta Pol. Pharm.,
         9, 127-148.

    Waterman, N. & Lignac, G.O.E. (1958). Long-term study in mice. Summary
         in Acta Physiol. Pharmacol. Neerl., 7, 35.

    Webb, J.M., Fonda, M., & Brouwer, E.A. (1962). Metabolism and
         excretion patterns of fluorescein and certain halogenated
         fluorescein dyes in rats. J. Fharmacol. Exp. Ther.,
         137, 141-147.

    Willheim, R. & Ivy, A.C. (1953). A preliminary study concerning the
         possibility of dietary carcinogenesis. Gastroenterology,
         23, 1-19.

    Witorsch, R.J., Jennings, A.S., & Schwartz, S.L. (1984). Effects of
         dietary FD&C Red No. 3 on the pituitary-thyroid axis of adult
         male rats. Report submitted to WHO by the Certified Color
         Manufacturers Association, Inc., Washington, DC, USA.

    Yoshii, H. & Isaka, H. (1984). Carcinogenicity study report on
         erythrosine. Unpublished report from the Dept. of Pathology,
         School of Medicine, Kashima (Japan) University. Submitted to WHO
         by the Japanese Ministry of Health and Welfare Research Group.
    


    See Also:
       Toxicological Abbreviations
       Erythrosine  (FAO Nutrition Meetings Report Series 46a)
       Erythrosine (WHO Food Additives Series 6)
       Erythrosine (WHO Food Additives Series 19)
       Erythrosine (WHO Food Additives Series 24)
       Erythrosine (WHO Food Additives Series 28)
       Erythrosine (WHO Food Additives Series 44)
       ERYTHROSINE (JECFA Evaluation)